#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Meghan Swardstrom Email
VP Clinical Development & Operation . Impel NeuroPharma
How to contact Meghan Swardstrom
Join and see Meghan's contact info for free!Current Roles
Employees:
143Revenue:
$44.9MAbout
Impel NeuroPharma, Inc., is a privately-held, Seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel's products are based on a novel nasal drug delivery platform, the POD device, that administers drug to the upper nasal cavity in a consistent and predictable manner. Impel NeuroPharma is currently investigating INP104 (POD DHE) for acute migraine headache, INP103 (POD levodopa) for Parkinson's Disease, INP105 (POD olanzapine) for agitation in schizophrenia and bipolar disorders as well as INP102 (POD insulin) for Alzheimer's disease in an NIH funded trial. Impel NeuroPharma's proprietary POD device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.Impel NeuroPharma Address
201 Elliott Avenue WSeattle, WA
United States